Mal-Val-Ala-PAB-N(SO2Me)-Exatecan TFA
Based on 1 Customer Validation
Mal-Val-Ala-PAB-N(SO2Me)-Exatecan TFA is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan TFA can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer.
For research use only. We do not sell to patients.
- Purity: 98.01%
- Formula: C58H66F4N8O17S
- Molecular Weight:1255.25
-
Storage:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Drug-Linker Conjugates for ADC Isoforms
More
Biological Activity
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1255.25
-
Formula C58H66F4N8O17S
-
Color Light yellow to yellow
-
SMILES
O=C(C=CC1=O)N1CCCCCC(N[C@@H](C(C)C)C(N[C@@H](C)C(NC(C=C2)=CC=C2COC(N(CCS(C)(=O)=O)COCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Guo Q, et al., FZ-AD005, A Novel DLL3-Targeted Antibody-drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Jun 28. [Content Brief]
[2]. Liu N, et al., Preparation method of linker drug conjugate and intermediate thereof. CN116178386.
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mal-Val-Ala-PAB-N(SO2Me)-Exatecan TFA Related Classifications
HY-159072A Related Classifications
Powered by Bioz